Tuesday, February 10, 2026
Hyderabad’s Curapod Therapeutics Raises INR 20 Cr Pre-Series A for Wearable PBM Pain Relief Device Targeting Arthritis, Back Pain, and Sports Injuries
The GMA Admin
Curapod Therapeutics, the Hyderabad-based healthtech innovator behind the Curapod device—a non-invasive, wearable solution leveraging photobiomodulation (PBM) technology for drug-free musculoskeletal pain management—has secured INR 20 crore ($2.4 million) in a Pre-Series A funding round. Led by V3 Ventures, 3i Partners, and ideaspring capital, the investment will fuel manufacturing scale-up, regulatory clearances for international expansion (including FDA approval targeted for early 2026), clinician partnerships, and nationwide distribution through wellness chains, physiotherapy networks, and e-commerce platforms. Founders Sri Velliyur (CEO) and Surya Maguluri (CTO) frame the raise as validation of Curapod’s clinically proven efficacy in treating over 30 conditions—from arthritis and back pain to sports injuries and plantar fasciitis—positioning it as India’s first adaptive, home-use PBM wearable bridging hospital-grade therapy with consumer accessibility.
Launched in 2024 under Litemed India Pvt Ltd, Curapod arrives amid rising demand for non-pharmacological pain solutions, as chronic musculoskeletal disorders affect over 200 million Indians, driving medication dependency and healthcare burdens. Priced at INR 8,999 per kit (including two devices, straps, adhesives, and charger for 1,000+ uses), it delivers red/near-infrared light pulses penetrating up to 70mm to stimulate ATP production, reduce inflammation, and accelerate cellular repair—backed by double-blind, multi-centric trials published in peer-reviewed journals and CDSCO licensing.
Clinical Innovation Meets Consumer Design: Curapod’s Technology Edge
Curapod redefines pain management by miniaturizing clinical PBM—once confined to high-end clinics—into a compact, USB-C rechargeable wearable with adaptive intensity adjustment via a companion app for personalized tracking and clinician remote monitoring. Unlike TENS units or generic heat pads, its targeted wavelengths (red/near-infrared) trigger molecular-level healing: boosting mitochondrial function for tissue rejuvenation, modulating inflammatory pathways, and providing sustained relief without systemic side effects or dependency risks.
Clinical validation sets it apart: placebo-controlled studies demonstrate significant pain reduction across tennis elbow, frozen shoulder, knee osteoarthritis, and chronic back pain, with results accessible via medical databases. The system’s portability—lightweight, ergonomic, with body straps and disposable patches—enables at-home or on-the-go use, appealing to urban professionals, athletes, seniors, and tier-2/3 city consumers underserved by specialist care. Early traction includes corporate wellness gifting and B2B clinician sales, with manufacturing fully localized in India for cost efficiency and supply chain resilience.
Velliyur emphasizes the dual audience: “For consumers, it’s seamless daily relief; for clinicians, data-driven outcomes with remote oversight—making Curapod a platform, not a gadget.” Maguluri adds engineering rigor: “We engineered hospital precision into home usability, with 1,000-treatment durability and app-guided protocols.”
Founders’ Vision: From Startup Event Synergy to Pain Relief Revolution
Curapod emerged in 2022 when Velliyur (systems engineering, operations) and Maguluri (optical science, clinical research) connected at a healthcare accelerator. Frustrated by India’s reliance on analgesics (projected INR 1.5 lakh crore market by 2026) and invasive therapies, they founded Litemed to democratize PBM—proven in NASA research and global clinics but inaccessible at scale.
A 16-member team (now expanding to 27) spans R&D, manufacturing, and go-to-market, bootstrapped until this raise. Key milestones: 2024 India launch via CDSCO approval, 35K monthly web traffic, and partnerships with physio chains for hybrid sales. The device targets a massive TAM: global PBM at $1.5B (20% CAGR), India pain management at INR 30,000 Cr, with Curapod claiming first-mover status in personalized wearables.
Funding Fuel: Scale, Compliance, and Market Penetration
The Pre-Series A—V3 Ventures (deeptech focus), 3i Partners (healthcare specialists), ideaspring capital (early-stage bets)—injects capital for critical levers:
- Manufacturing Ramp: Boost capacity from current lines to support 10x volume, targeting tier-2/3 penetration via distributors.
- Regulatory Push: FDA clearance by Q1 2026 for US/EU entry, plus additional CDSCO nods for expanded indications.
- GTM Expansion: E-commerce (own site, Amazon), B2B clinician networks, corporate wellness programs; marketing via digital, physio endorsements, and trials.
- R&D Iteration: App enhancements (AI-driven protocols), device variants (e.g., larger areas), clinical trials for new conditions.
Investor rationale: Curapod’s 80%+ user retention in pilots, peer-reviewed data, and Made-in-India edge amid Atmanirbhar push. ideaspring’s portfolio synergy (healthtech like Dozee) accelerates validation.
Market Context: Disrupting Pharma-Dominated Pain Relief
India’s pain market skews pharmacological (80% NSAIDs), with side effects fueling demand for alternatives—PBM adoption lags due to clinic costs (INR 2,000/session). Curapod undercuts at INR 25/use long-term, matching efficacy sans risks. Competitors like Omron (TENS) lack cellular-depth; global players (NovoTHOR) target enterprises. Curapod’s home/clinical hybrid, app personalization, and affordability carve a blue ocean.
Challenges: Consumer education on PBM, reimbursement hurdles, competition from cheap imports. Mitigations: clinician tie-ups (80% Tier-1 physio adoption goal), endorsements (e.g., Dr. Vinod Kumar’s trials), and pilots proving 40-60% pain drop in 2 weeks. International whispers: EU distributor talks post-FDA.
Growth Trajectory: From Hyderabad to Global Pain Leadership
2026 roadmap: 1 lakh units sold, 5x revenue via exports (US wellness, EU physio), Series A prep. Team growth to 50, with sales/marketing hires. Velliyur: “We’re not selling devices; we’re enabling pain-free lives—scalable, evidence-based.” Maguluri: “Clinical depth meets consumer scale—India first, world next.”
For investors, Curapod embodies healthtech convergence: validated tech, domestic manufacturing, massive unmet need. In a post-pandemic wellness boom, this raise positions Litemed as PBM’s Indian vanguard—turning light into relief, one wearable at a time.